TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
IPO Year: 2019
Exchange: NASDAQ
Website: tffpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2022 | $22.00 | Buy | H.C. Wainwright |
DEF 14A - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
PRE 14A - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
8-K - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
10-Q - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
NT 10-Q - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
8-K - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
8-K - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
10-Q - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
8-K - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
8-K - TFF Pharmaceuticals, Inc. (0001733413) (Filer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)
FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. The Company expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about February 16, 2025. The removal of the Common Stock from Nasdaq will be effective 10 days after the filing of the Form 25. The Company has made no arrangements for
FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of office
FORT WORTH, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (NASDAQ:TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announces positive preclinical data published in the Journal of Drug Delivery Science and Technology further validating the Company's TFF technology as superior approach to formulate dry powders for pulmonary drug delivery. The study demonstrates the superiority of TFF inhalational dry powders over jet-milling and spray-drying technologies in a rat model, with enhanced uniform drug
Partnership funded by BARDA and other US government agencies TFF formulation may provide flexibility of delivery and improve storage and distribution conditions FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (NASDAQ:TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announces its new partnership with Emory University and the Biomedical Advanced Research and Development Authority (BARDA). Under the partnership, TFF Pharmaceuticals will test the feasibility of converting Emory's m
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to assess additional influenza strains FORT WORTH, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (NASDAQ:TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announces positive preclinical data advancing a multivalent universal influenza vaccine manufactured by TFF to protect against seasonal and pandemic viruses. The data were produced in collabo
FORT WORTH, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Dr. Harlan Weisman, CEO, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel. Presentation Date:September 9, 2024Time:Available on-demand starting at 7:00 AM Eastern TimeWebcast Link:https://journey.ct.events/view/2ab5063d-1d8d-4439-8667-a87907f48d97 A webcast of t
FORTH WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter 2024 and provided a corporate update. "Over the last several months, we have amassed a growing body of positive safety, efficacy and confirmatory biomarker data from our Phase 2 program that points towards TFF TAC becoming a significant new advancement for the prevention of lung transplant rejection," said Harlan Weisman, M.D., Chief Executive
Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood levels -- leading to diminished drug burden 9 out of 9 (100%) patients who completed the 12-week treatment chose to remain on TFF TAC by proceeding to the long-term extension Phase; 2 patients have been treated for over a year and 6 patients have been treated for more than 6 months Observed a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC No production of donor-specific antibodies (DSA) after treatment wi
FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities. "We are pleased to announce this engagement with Outcome Capital, which is a well-recognized investment bank specializing in corporate advisory services to the life sciences industry," said Dr. Harlan Weisman, Chief Executive Officer
FDA Provided Constructive Feedback to Help Guide Next Steps in TFF TAC Clinical Development Company to Provide More Detailed Regulatory Update in 3Q 2024 FORT WORTH, Texas, June 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced a regulatory update on the Company's TFF TAC clinical program following its recent interaction with the U.S. Food and Drug Administration (FDA). In April 2024, the Company submitted a briefing book to the FDA to help guide the next steps
H.C. Wainwright resumed coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $22.00
HC Wainwright reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $37.00 from $31.00 previously
HC Wainwright & Co. reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $37.00 from $31.00 previously
Roth Capital reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $27.00 from $23.00 previously
HC Wainwright resumed coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $31.00
H.C. Wainwright initiated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $31.00
B. Riley resumed coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $36.00
SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)
Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate Antifungal Activity and a Favorable Safety and Tolerability Profile TFF TAC Program Prioritized Based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Hold Conference Call and Webcast Today at 4:30 pm ET FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing
Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Evaluate Strategic Options for TFF VORI, including Partnerships, Collaborations, and Grants following Positive Data from Phase 2 Study and the Expanded Access Program (EAP) Company to Discuss Clinical Updates on TFF TAC and TFF VORI on Wednesday, March 27, 2024 at 4:30 pm ET FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing an
Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE) Successful transition of all four patients from oral tacrolimus to TFF TAC, leading to significant lowering of tacrolimus blood levels with no clinical evidence of acute rejection; all patients who completed Part A (study treatment period) of the trial chose to remain on TFF TAC and advance to Part B (extension study) TFF TAC was well tolerated, with no mortality a
FORT WORTH, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company will hold a conference call and webcast to review initial data from the ongoing Phase 2 trials of TFF VORI and TFF TAC on Tuesday, December 19th at 8:30 am ET. Conference Call and Webcast InformationTo participate in the conference call, please utilize the following information: Domestic Dial-In Number: Toll-Free: 1-877-407-3982 International Dial-In Number: 1-201-493-6780
FORT WORTH, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it management will host a conference call to discuss the financial results for the second quarter of 2023 and provide an update on recent corporate and clinical developments on Tuesday, August 15, 2023, at 11:00 AM ET. A question-and-answer session with investors will follow management's remarks. Conference Call and Webcast Information The Company will host a conference call on Tuesday, August 15, 20
Initial Phase 2 data for TFF VORI and TFF TAC expected later this yearExpanded compassionate use program for TFF VORIEntered into CRADA with National Institute of Environmental Health Sciences Extended contract with Leidos providing additional funding for TFF's development of next-generation countermeasuresImplemented reduced spending initiatives to extend cash runway through year-end FORT WORTH, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financi
Dr. Harlan Weisman and recently appointed Chief Medical Officer Dr. Zamaneh Mikhak to Provide an Overview of the Corporate Strategy and 2023 Objectives Conference Call and Webcast Scheduled for Thursday, February 16, 2023, 4:30 p.m. ET FORT WORTH, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Harlan Weisman, M.D. as permanent Chief Executive Officer. TFF Pharmaceuticals will hold a conference call and webcast on February 16 to provide an ove
Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI) Growing Body of Peer-Reviewed Scientific Literature Provides Foundations for Expanding Applications of Thin Film Freezing Feasibility Study Agreement with Aptar Pharma to Explore Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics Conference Call and Webcast Scheduled Today, Monday, November 14, 2022, at 4:30 PM ET FORT WORTH, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thi
Company conference call and webcast at 4:30 PM ET FORT WORTH, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it will release its financial results and business update for the third quarter of 2022 on Monday, November 14, 2022, at the close of the U.S. financial markets. Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at 4:30 PM ET. A question-and-answer session with investo
Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance Expands R&D Operations with New Austin, TX Facility Recent Feasibility Work Confirms Utility of Thin Film Freezing in Developing Next- Generation Vaccines Conference Call and Webcast Scheduled Today, Thursday, August 11, 2022, at 4:30 PM ET FORT WORTH, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter of 202
FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of office
FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. "I am pleased to welcome Thomas King to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will p
FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors. "I am pleased to welcome Dr. Patane to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Mike's career spans over two decades of leadership experience in drug discovery and development, and he has demonstrated an extraordinary ability to turn scientific success into corp
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer. Dr. Mikhak will be responsible for the clinical development of the Company's pipeline candidates, including the Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder clinical programs. "We are pleased to welcome Dr. Mikhak to TFF Pharmaceuticals as our Chief Medical Officer," said Dr. Harlan Weisman, Interim Chief Executive Officer of TFF Phar
Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer FORT WORTH, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that Glenn Mattes will step down as Chief Executive Officer and Member of the Board of Directors. Dr. Harlan F. Weisman, Vice Chairman of the Board, has been appointed Interim Chief Executive Officer, effective Decembe